Cellenkos Receives FDA Clearance for Phase 2 Trial of CK0801 in Aplastic Anemia Patients
Cellenkos, Inc., a biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial for CK0801, a treatment for aplastic anemia. This rare and life-threatening blood disorder is characterized by the bone marrow's failure to produce essential blood cells, often due to an autoimmune attack. The trial will evaluate the safety and efficacy of CK0801, which is derived from allogeneic cord blood and aims to restore immune balance and reduce transfusion dependency. The study targets adults who have failed previous treatments and are reliant on transfusions. CK0801 has shown promise in Phase 1 trials, with some patients achieving transfusion independence. 
